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MinireviewNo DREAM, No Pain:
Closing the Spinal Gate
analgesia without any evidence of  receptor desensiti-
zation, or substantial motor or behavioral abnormalities.
The specific effect of the DREAM null mutation, appar-
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ently limited to a reduction in pain, is rather surprising,Massachusetts General Hospital and Harvard
given the multiple functions attributed to this protein.Medical School
DREAM has also been christened calsenilin and KChIP3,Massachusetts General Hospital-East
and has been found to modulate potassium channels,Charlestown, Massachusetts 02129
proteolytic processing (references in Cheng et al., 2002),
and apoptosis (Sanz et al., 2001). These diverse roles,
coupled with multiple potential target genes for tran-
scriptional repression, might have suggested that thePain transmission in the spinal cord is regulated by a
knockout would have a more widespread effect thanbalance of facilitatory and inhibitory influences op-
observed by Cheng and colleagues. Future analysis mayerating on the neural circuits of the somatosensory
reveal additional more subtle phenotypes.system. The transcriptional repressor DREAM acts
The Pain Gateconstitutively to suppress prodynorphin expression in
Until the 1960s, the prevailing model for the neural gen-spinal cord neurons. Knocking out DREAM results in
eration of pain was essentially Cartesian: a fixed andsufficient dynorphin expression to produce a strong
dedicated pain pathway was thought to link the site ofreduction in generalized pain behavior, highlighting
a peripheral noxious stimulus to the brain site where thethe role that intracellular molecules play in modulating
perception of pain occurs. In this model, the nature,pain gating in the spinal cord.
intensity, and duration of the pain sensation were con-
sidered a passive reflection of the qualities of the periph-Dynorphin is an endogenous ligand for the  opiate
eral stimulus. The nervous system was believed to es-receptor, which, along with the  and  receptors, is a
sentially act as a hardwired telephone link, with themember of the opiate G protein-coupled receptor family.
spinal cord merely a switchboard operator dialing theAgonists of these receptors are major candidate drugs
appropriate connection between a peripheral noxiousfor pain control. Morphine, the gold standard for analge-
stimulus and the central pain response.sics, acts via the  receptor to both activate potassium
The first major challenge to this view was that of thechannels and block calcium currents, reducing mem-
Spinal Gate Control Theory proposed by Pat Wall andbrane excitability and transmitter release (Pasternak,
Ron Melzack in 1965 (Melzack and Wall, 1965). Based2001). However, receptor activation also affects cogni-
on a mixture of clinical observation and insights fromtion, perception, mood, respiration, and gastro-intesti-
systems neurophysiology and neuropsychology, theynal function, and clinical use of  agonists leads to
proposed that input signals from primary sensory neu-tolerance, withdrawal, and addiction. Would  and 
rons were actively modulated in the spinal cord by aagonists be better analgesic drugs than  agonists?
“gate.” Which signals were let through, and thereforeThis is not clear:  agonists have not been tested in
relayed to the brain, depended on a balance betweenpatients yet, and the analgesia produced by  agonists
inhibitory and facilitatory influences both arising locallycan be complicated by dysphoria and diuresis.
and descending from the brain. Although specific ele-What about activating the opiate receptors via their
ments of this theory have been shown to be invalid orendogenous ligands to produce analgesia?  endorphin
too simplistic, the fundamental model remains. Namely,
and the enkephalins, the endogenous ligands for  and
pain does not arise solely from the faithful relay of sig-
 receptors, have been repeatedly proposed to act as
nals from primary somatosensory neurons to the brain,
humoral and synaptic modulators of pain. However, but is subject to other modulatory signals and is depen-
other than in specific circumstances related to stress dent on prior experience. At one extreme, pain modula-
and placebo, their mechanisms of release are poorly tion is sufficiently powerful that under certain circum-
understood. Now, Cheng and coworkers (2002) have stances massive tissue injury may be sustained without
found that mice with a null mutation in the repressor producing pain. Recruitment of the body’s multiple en-
DREAM possess a marked reduction in generalized pain dogenous inhibitory control mechanisms to shut down
behavior, effectively displaying a phenotype of ongoing pain when necessary for survival purposes has been
analgesia. This finding is attributed to the removal of a observed repeatedly in war casualties. At the opposite
constitutive block by DREAM of dynorphin expression in extreme, previously innocuous stimuli, such as lightly
spinal cord neurons. DREAM, by suppressing dynorphin touching or blowing on the skin, can become excruciat-
levels in the spinal cord, appears to regulate pain trans- ingly painful under certain pathological situations. More-
mission by controlling the level of  receptor activation, over, following peripheral inflammation, a lesion to a
offering a new possibility for managing pain. Dynorphin peripheral nerve, or damage to the central nervous sys-
derepression, by blocking DREAM’s action, would ap- tem, pain can arise in the absence of any detectable
pear to be an attractive therapeutic opportunity because peripheral stimulus.
animals with a null mutation for DREAM show persistent What Controls the Pain Gate?
Most efforts until now have examined two general pro-
cesses that can control the pain gate. First, inhibitory1Correspondence: woolf.clifford@mgh.harvard.edu
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that the DRE element is functional in both directions
downstream, but not upstream, of the TATA box, sug-
gests that it physically impedes the progress of the RNA
polymerase II complex (Ledo et al., 2000). A 32 kDa
protein was isolated from a human caudate expression
library using a double-stranded oligonucleotide encod-
ing the DRE sequence as a probe (Carrion et al., 1999).
Coexpression of this protein with a reporter plasmid
containing the prodynorphin promoter showed that the
protein was capable of repressing basal dynorphin ex-
pression, and other reporter assays confirmed that re-
pression is effected through the DRE site. In naming
this protein, Carrion and coworkers coined the acronym
DREAM because the protein binds to the DRE sequence
and acts as a silencer or antagonist modulator (Carrion
et al., 1999).
DREAM binds the prodynorphin promoter as a tetra-
mer to form the 110 kDa complex (Carrion et al., 1998,
1999). DREAM’s primary structure contains four calcium
chelating EF-hand motifs, which site-directed mutations
show bind calcium and then prevent DREAM repression
of the prodynorphin promoter (Carrion et al., 1999) (Fig-
ure 1). In neuroblastoma cell lines, however, prodynor-
phin de-repression is PKA mediated, a surprising find-
ing, since DREAM does not contain any PKA phos-
phorylation consensus sites (Carrion et al., 1998; Carrion
et al., 1999). This apparent paradox was solved when it
was found that CREM and DREAM form complexesFigure 1. Dynorphin Transcription Is Determined by a Balance be-
that are strengthened by PKA mediated CREM phos-tween Repression and Transactivation
phorylation (Ledo et al., 2000). When CREM interactsThe transcriptional repressor DREAM, which is constitutively ex-
pressed in certain neurons, binds to a downstream response ele- with DREAM, the complex is released from the DRE site,
ment (DRE) on the prodynorphin gene, blocking RNA polymerase enabling prodynorphin transcription (Ledo et al., 2000)
II, and thereby transcription. DREAM binding to the DRE site can (Figure 1).
be terminated either by calcium entry into the nucleus and binding
Neuronal Activation by Noxious Inputsdirectly with DREAM or by a PKA-mediated phosphorylation of
Noxious stimuli activate high threshold primary sensoryCREM, both of which are likely to occur after activation of the neuron.
Prodynophin transcription is also regulated by transactivators in- neurons in the periphery. This activity is conducted to
cluding CREB binding to CRE, and c-fos with c-jun to an AP-1 their central terminals, which synapse on second order
site. CREB activation and c-fos levels are regulated by activity- nociceptive neurons in the spinal cord. Brief inputs car-
dependent activation of PKA and the MAPK ERK.
ried by the sensory neurons, generated in response to
transient non tissue-damaging noxious stimuli, excite
neuronal circuits synapse onto nociceptive transmission the dorsal horn neurons via the synaptic release of gluta-
neurons in the spinal cord and act as bouncers at the mate which activates AMPA/kainate ligand-gated ion
door, keeping out undesirable inputs (Fields and Bas-
channels. The resulting fast synaptic depolarizations en-
baum, 1999). Second, excitatory mechanisms can sensi-
code the duration, intensity, and location of the stimulus
tize central neurons, allowing uninvited gatecrashers
(Woolf and Salter, 2000).
into the pain party (Woolf and Salter, 2000). While pain
The more intense or sustained noxious stimuli associ-needs to be examined and understood at a systems
ated with tissue damage result in temporal summationlevel, it now appears that in addition to extrinsic pain
of postsynaptic depolarizations. Temporal summationgating mechanisms, a series of intracellular switches
removes the voltage-dependent magnesium block ofcontribute to the intrinsic gating of pain. Through regula-
NMDA glutamate receptors and activates voltage-gatedtion of dynorphin levels in spinal cord neurons, Cheng
calcium currents, causing a substantial calcium influx.et al. (2002) show that DREAM acts to repress a pain
Intense stimulation of nociceptors also activates meta-inhibitor. In a Ying and Yang-like balance, opposing
botropic glutamate, neuropeptide GPCR receptors, andforces control molecular switches in the spinal cord.
tyrosine kinase receptors as a result of the synapticThese switches can either allow or, like DREAM, deny
release of glutamate, substance P, and BDNF. Activationexpression of pain regulating molecules.
of these receptors, together with the calcium influx, initi-DREAM and Dynorphin
ate increases in the excitability of spinal neurons, theDREAM was discovered in a search for proteins that
phenomenon of central sensitization. Central sensitiza-bind to an element that follows the transcription start site
tion results in increased synaptic efficacy, and therebyin the promoter region of the dynorphin gene (Carrion et
a spread of pain sensitivity beyond the site of injuryal., 1999). Earlier work had shown that a 110 kDa nuclear
(secondary hyperalgesia) and the generation of pain incomplex binds to a downstream regulatory element
response to low threshold inputs (allodynia) (reviewed(DRE) of the prodynorphin gene, and that this binding
repressed dynorphin transcription (Figure 1). The fact in Woolf and Salter, 2000).
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Figure 2. Molecular Switches Controlling Dy-
norphin Expression in Different Sets of Spinal
Cord Neurons Can Potentially Facilitate or
Suppress Pain Transmission
Dynorphin expression induced in inhibitory
interneurons that innervate pain transmission
neurons, by reducing the activity of these
neurons, will facilitate pain transmission pro-
ducing hyperalgesia (A). Dynorphin expres-
sion that reduces input to or activity of the
pain transmission neurons themselves will re-
sult in analgesia (B).
Molecular Switches that Open and Close a facilitator depending on how and where it is expressed,
and on which neurons it acts.the Pain Gate
Several activity-dependent events driven by noxious in- Preprodynorphin precursor protein is broken up into
different peptides; some are highly selective for  recep-puts, such as calcium influx, the activation of PKA, and
the pERK/pCREB pathway, initiate alterations in tran- tors and others are non-opiate in their action, and each
may contribute to dynorphin’s different roles (reviewedscription in dorsal horn neurons. Calcium binding to
DREAM on entry into the nucleus would produce a dere- in Laughlin et al., 2001). Pharmacological and prodynor-
phin gene knockout data suggests that under some cir-pression of genes whose promoter contains a DRE site
(Figure 1), including c-fos and prodynorphin. PKA would cumstances dynorphin can actually act as a hyperalge-
sic agent—creating pain (Laughlin et al., 2001). At highalso initiate a derepression of DREAM, though in this
case through CREM. Induction of CREM (Naranjo et concentrations, dynorphin activates the NMDA recep-
tor, which would facilitate pain by inducing central sensi-al., 1997) and activation of ERK and CREB (Ji et al., 2002)
occur in the spinal cord following noxious stimulation, tization. Moreover, dynorphin acting via  receptors may
not only inhibit activity in nociceptive transmission neu-as do increases in c-fos and prodynorphin expression
rons, producing analgesia, but may also inhibit the many(Naranjo et al., 1991). Surprisingly, in the DREAM knock-
inhibitory interneurons in the spinal cord (Figure 2).out, no constitutive elevation of c-fos in the spinal cord,
Dampening inhibitory neuron activity would lead to annor of dynorphin in whole brain preparations was ob-
overall increase in excitability of nociceptive neuronsserved, implying that regulation through DRE occurs
(disinhibition), another example of the balance of forcesin a more complex context of multiple tissue specific
operating in the pain pathway. It is essential, therefore,repressors and transactivators. Changes in spinal cord
to identify which cells in the dorsal horn of the spinallevels of c-fos following nociceptive input, as well as
cord express dynorphin in response to DREAM dere-region-specific differential expression of prodynorphin
pression and after inflammation, and in addition estab-in the brain of the DREAM null mutant animals would
lish on which cells dynorphin acts. Does dynorphin actbe of interest in future studies, as would the functional
via  receptors on presynaptic primary afferent inputsconsequence of the increased dynorphin expression
preventing activation of spinal cord nociceptive neu-found in ventral horn neurons.
rons, or by a direct postsynaptic inhibition of these neu-Prodynorphin expression is driven by c-fos and c-jun,
rons? Conversely, is dynorphin’s effect directed ontowhich bind a noncanonical AP-1 element in the dynor-
inhibitory interneurons? Action on inhibitory interneu-phin promoter (Naranjo et al., 1991), and by three CREB
rons will open the pain gate, while action on pain trans-binding CRE consensus sites (Cole et al., 1995) (Figure
mission neurons will close it (Figure 2).1). Inhibition of the MAPK cascade leads to a reduction
Given the heterogeneity of neurons and their circuits,of prodynorphin, and of pain hypersensitivity (Ji et al.,
the result of opening or closing a single molecular switch2002). If dynorphin is a negative pain regulator, as the
is, not surprisingly, very complex. Since millions of indi-DREAM knockout suggests, why does reducing it by
viduals suffer from chronic pain, teasing out these mech-inhibiting ERK activation inhibit pain? There are two
anisms, although daunting, is essential if we are to standpossible explanations. The first is that the MAPK signal
any hope of controlling the pain gate within patients.transduction cascade is permissive, acting on many tar-
The study by Cheng et al. is nevertheless an encouraginggets that may exert both positive and negative influ-
first step.ences on excitability. While the net effect of MAPK inhi-
Sweet DREAMs are made of this. Who am I to dis-bition is to reduce pain hypersensitivity by blocking
agree?transcription of pain promoting genes like NK1 (Ji et al.,
2002), it also reduces prodynorphin levels, which may
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